Flagship explainer
What drives Elite Pharmaceuticals, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $44.9M | FY2026 |
| |
| Income before tax | $56.8M | FY2026 |
|
| Operating income | $49.1M | FY2026 |
|
| $149M | FY2026 |
| |
| Ending assets | $138M | FY2026 |
|
| Beginning assets | $96.4M | FY2025 |
|
| $98.9M | FY2026 |
| |
| $53.5M | FY2025 |
|
Source:
- SEC filingFiling detailsAccession 0001493152-26-031070